Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Company Overview - Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, a novel antibody therapy targeting c-Kit (CD117) for mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [1][3] - Briquilimab is an aglycosylated monoclonal antibody that inhibits the binding of stem cell factor to c-Kit, leading to the depletion of mast cells and addressing the inflammatory response in these diseases [3] Clinical Development - Jasper is currently conducting clinical studies of briquilimab for patients with CSU, CIndU, and asthma, demonstrating efficacy and safety in previous trials [3] - Positive clinical outcomes have been reported for briquilimab in treating CSU and CIndU [3] Upcoming Events - Jasper's management will present at the Oppenheimer Healthcare Life Sciences Conference on February 11, 2025, at 3:20 p.m. EST, in a fireside chat format [2] - A live webcast of the presentation will be available on Jasper's Investor Relations website, with an archived replay accessible for 30 days post-event [2]